Amphora, PatentSafe, and Glycomar

Unlike some vendors, we tend not to make a fanfare when we get new customers – partly because it gets a bit boring after a while, and partly because, well, that’s a kind of “stretch things as far as you can” marketing we’d really not get into.

However, we’re also conscious that sometimes we don’t portray ourselves in the best light especially when other people are press releasing a small pilot in one area of a company as a “Global Rollout”. We’re probably the largest vendor in our space by a large margin but you wouldn’t believe that from the hype sometimes!

So we’ve started to look at press releasing some of our customer wins. We’ve made a bunch of people happy and I guess there’s no harm in telling the world sometimes….

As part of that a press release went out last night regarding Glycomar’s use of PatentSafe, particularly the PatentSafe starter pack which is ideal for their circumstances.

Without further ado, here’s the press release which pretty much says it all….

Amphora’s PatentSafe Solution Selected by Glycomar

Amphora Research Systems , a key provider of electronic laboratory notebook (ELN) products for the biotech industry, announces the purchase of Amphora’s PatentSafe Starter Pack for researchers at Glycomar – a marine biotechnology company dedicated to the discovery, development and commercialisation of new anti-inflammatory drug candidates based on the glycobiology of marine organisms. Glycomar is using Amphora’s PatentSafe solution as a fully-electronic ELN, with digital signatures for legal patent evidence. By using PatentSafe not only do they create secure records for patents but also they have the benefit of a searchable, sharable repository of the company’s research.

(PRWEB) April 18, 2008 — Amphora Research Systems (http://www.amphora-research.com), a key provider of electronic laboratory notebook (ELN) products for the biotech industry, announces the purchase of Amphora’s PatentSafe Starter Pack for researchers at Glycomar – a marine biotechnology company dedicated to the discovery, development and commercialisation of new anti-inflammatory drug candidates based on the glycobiology of marine organisms.

Glycomar is using Amphora’s PatentSafe solution as a fully-electronic ELN, with digital signatures for legal patent evidence. By using PatentSafe not only do they create secure records for patents but also they have the benefit of a searchable, sharable repository of the company’s research.

April Macleod from Glycomar said “Being a small Biotech, most Electronic Lab Notebook solutions were too involved and expensive, but Amphora’s PatentSafe Starter Pack option is perfect for our situation and can easily meet our needs as we grow”.

Simon Coles, CTO and co-founder of Amphora, explains: “There’s a real need for a practical, approachable ELN solution for the hundreds of small Biotechs who need the significant productivity gains that come with an ELN, with full protection for their patents. Most ELN solutions on the market were built to serve the needs of Big Pharma, but the PatentSafe Starter Pack is focused exactly on the smaller Biotech companies. We have designed the system so that it is a “plug & play” set up, we were able to get Glycomar up and running on the system within a couple of hours. Because of the way PatentSafe fitted into the scientists’ existing working patterns, rolling out the system was smooth and pain free for both parties.”

Thanks to PatentSafe, scientists can work using whatever tools suit their research needs best and still collaborate easily on their projects. Scientists no longer have to ‘cut and stick’ computer printouts into their traditional bound laboratory notebook, saving typically between 15 minutes to an hour per day. Furthermore, the entire PatentSafe notebook can be searched and shared with colleagues and all work is fully protected for patent and IP purposes. PatentSafe is quick to learn and affordable to deploy, and can be used in conjunction with traditional paper-based methods or in fully electronic mode using secure digital signatures.

###